For critically ill COVID-19 patients, the immune battles fought inside the ICU extend well beyond SARS-CoV-2 itself. This analysis challenges the still-common clinical assumption that latent herpesvirus reactivation in ICU patients is an epiphenomenon — a bystander finding rather than a driver of harm — and suggests that at least one of these viruses may carry real mortality weight.
In a retrospective review of 455 consecutive ICU admissions at a single center during the first two years of the pandemic, viral reactivation of either herpes simplex virus type 1 (HSV-1) or cytomegalovirus (CMV) was detected in 36% of patients. HSV-1 reactivation emerged as an independent predictor of mortality after multivariable adjustment, with ICU survival dropping dramatically — 32% versus 67% in patients without HSV-1 detection. Co-reactivation of both viruses occurred in 13% of cases, while isolated HSV-1 and isolated CMV each appeared in approximately 12%. Reactivation events tended to cluster within the first four days of ICU admission, with frequency increasing alongside length of stay. HSV-1 specifically — but not CMV — was associated with greater requirements for invasive mechanical ventilation, veno-venous ECMO, and renal replacement therapy. Higher neutrophil-to-lymphocyte ratios were also independently linked to outcomes.
The biological plausibility here is real: HSV-1 can directly injure pulmonary epithelium and amplify systemic inflammatory signaling, potentially compounding the cytokine-driven injury already central to severe COVID-19. This finding aligns with earlier smaller studies in non-COVID ICU populations that flagged HSV-1 as a meaningful complication rather than mere marker of illness severity. The critical limitation is the retrospective, single-center design — causality cannot be established, and confounding by illness severity remains a serious concern despite multivariable adjustment. Whether antiviral treatment of HSV-1 reactivation improves survival is a question this study cannot answer, making prospective interventional trials the essential next step. For now, this adds meaningful weight to the case for routine herpesvirus surveillance in critically ill COVID-19 patients.